The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
European expert consensus statement on therapeutic goals in Fabry disease
Open accessAbstract
BACKGROUND Fabry disease, an inherited lysosomal storage disorder, causes multi-organ pathology resulting in substantial morbidity and a reduced life expectancy. Although Fabry disease is an X-linked disorder, both genders may be affected, but generally to a lesser extent in females. The disease spectrum ranges from classic early-onset disease to non-classic later-onset phenotypes, with complications occurring in multiple organs or being confined to a single organ system depending on the stage of the disease. The impact of therapy depends upon patient- and disease-specific factors and timing of initiation. METHODS A European panel of experts collaborated to develop a set of organ-specific therapeutic goals for Fabry disease, based on evidence identified in a recent systematic literature review and consensus opinion. RESULTS A series of organ-specific treatment goals were developed. For each organ system, optimal treatment strategies accounted for inter-patient differences in disease severity, natural history, and treatment responses as well as the negative burden of therapy and the importance of multidisciplinary care. The consensus therapeutic goals and proposed patient management algorithm take into account the need for early disease-specific therapy to delay or slow the progression of disease as well as non-specific adjunctive therapies that prevent or treat the effects of organ damage on quality of life and long-term prognosis. CONCLUSIONS These consensus recommendations help advance Fabry disease management by considering the balance between anticipated clinical benefits and potential therapy-related challenges in order to facilitate individualized treatment, optimize patient care and improve quality of life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., et al. (2014) · Stroke · doi:10.1161/str.0000000000000024 · Cited by 5,170
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy
Authors/Task Force members, Elliott, P. M., Anastasakis, A., Borger, M. A., Borggrefe, M., Cecchi, F., Charron, P., Hagege, A. A., Lafont, A., Limongelli, G., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu284 · Cited by 4,332 · cited 2×
“Arrhythmia (see ESC hypertrophic cardiomyopathy guidelines [45]) Ventricular arrhythmia Prevent sudden cardiac death by implantation of an implantable cardioverter defibrillator in patients with sustained ventricular arrhythmia or features suggestive of increased sudden death risk Atrial fibrillation/flutter Preve…”
BackgroundSelf-citationPharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., Gilron, I., Haanpää, M., Hansson, P., Jensen, T. S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70251-0 · Cited by 3,980 · cited 1×
“To manage the neuropathic pain symptoms, adjunctive pharmacotherapy should follow recommendations for neuropathic pain states of other aetiologies [116,117].”
BackgroundSelf-citationStool form scale as a useful guide to intestinal transit time
Lewis, S. J., & Heaton, K. W. (1997) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529709011203 · Cited by 3,244 · cited 2×
“Gastrointestinal dysfunction General goal Mitigation of GI symptoms to improve QoL Monitor GI symptoms using validated GI rating scales (Rome III or the GSRS [140,141], the Bristol stool form scale [142])”
BackgroundMethodEFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision
Attal, N., Cruccu, G., Baron, R., Haanpää, M., Hansson, P., Jensen, T. S., & Nurmikko, T. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.02999.x · Cited by 1,873
Self-citationSerum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease
Lenders, M., Stypmann, J., Duning, T., Schmitz, B., Brand, S.-M., & Brand, E. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014121226 · Cited by 133
Cited by
Lysosomal storage disease overview
Sun, A. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.11.39 · Cited by 271
Metadata
- Authors
- Wanner, C., Arad, M., Baron, R., Burlina, A., Elliott, P. M., Feldt-Rasmussen, U., Fomin, V. V., Germain, D. P., Hughes, D. A., Jovanovic, A., Kantola, I., Linhart, A., Mignani, R., Monserrat, L., Namdar, M., Nowak, A., Oliveira, J.-P., Ortiz, A., Pieroni, M., Spada, M., Tylki-Szymańska, A., Tøndel, C., Viana-Baptista, M., Weidemann, F., & Hilz, M. J.
- Venue
- Molecular Genetics and Metabolism
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 124
- Issue
- 3
- Pages
- 189-203
- ISSN
- 1096-7192 (ISSN-L)
- OpenAlex
- W2808184073
- Cited by
- 208
- References
- 8
- FWCI
- 11.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: European expert consensus statement on therapeutic goals in Fabry disease. https://app.cochat.ai/papers/10.1016/j.ymgme.2018.06.004
- The paper
- Wanner, C., Arad, M., Baron, R., Burlina, A., Elliott, P. M., Feldt-Rasmussen, U., Fomin, V. V., Germain, D. P., Hughes, D. A., Jovanovic, A., Kantola, I., Linhart, A., Mignani, R., Monserrat, L., Namdar, M., Nowak, A., Oliveira, J.-P., Ortiz, A., Pieroni, M., . . . Hilz, M. J. (2018). European expert consensus statement on therapeutic goals in Fabry disease. Molecular Genetics and Metabolism. https://doi.org/10.1016/j.ymgme.2018.06.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.